Posted on: Friday, 10 October 2008, 09:00 CDT WILMINGTON, Del., Oct. 10 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR(R) (quetiapine fumarate) Extended-Release Tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex. SEROQUEL XR is the first medication approved by the FDA for the once-daily acute treatment of both depressive and manic episodes associated with bipolar disorder.(1) "When people think about bipolar disorder it is important to remember how debilitating the depressive episodes of the disease can be. In fact, in the long term,...
[read full story]
Your Web Site
